HYDRALYTE_1170x120

Joseph Jimenez

P&G names Jimenez, Peltz to board after proxy fight

P&G names Jimenez, Peltz to board after proxy fight

CINCINNATI — After a lengthy proxy battle, Procter & Gamble Co. has named Novartis chief executive officer Joseph Jimenez and activist investor Nelson Peltz as directors. Jimenez and Peltz, co-founder of Trian Fund Management, are slated to join the board on March 1. Their additions will expand the P&G board from 11 to 13 members.

Amgen CEO elected as PhRMA chairman

Amgen CEO elected as PhRMA chairman

WASHINGTON — Pharmaceutical Research and Manufacturers of America (PhRMA) has named Amgen Inc. chairman and chief executive officer Robert Bradway as chairman-elect. Bradway will succeed Joaquin Duato, executive vice president and worldwide chairman of pharmaceuticals at Johnson & Johnson, as PhRMA chairman in February 2018. Previously, Bradway served as board treasurer for PhRMA. Sanofi CEO

Novartis CEO Joseph Jimenez to step down

Novartis CEO Joseph Jimenez to step down

BASEL, Switzerland — Novartis chief executive officer Joseph Jimenez plans to retire from the company next year, to be succeeded by drug development chief Vasant Narasimhan. Plans call for Jimenez to step down on Jan. 31, 2018, and for Narasimhan, who is global head of drug development and chief medical officer at Novartis, to take

PhRMA elects officers, welcomes new member UCB

PhRMA elects officers, welcomes new member UCB

WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors has elected new officers and ushered in a new member company. Joaquin Duato, worldwide chairman of pharmaceuticals at Johnson & Johnson, was elected chairman. Joseph Jimenez, chief executive officer of Novartis AG, was elected chairman-elect, and Amgen chairman and CEO Robert Bradway

Novartis realigns pharma division into two new units

Novartis realigns pharma division into two new units

BASEL, Switzerland — Making changes to its Pharmaceuticals Division, Novartis has created two business units that will report to the chief executive officer: Novartis Pharmaceuticals and Novartis Oncology. The new units will form the Innovative Medicines Division. Novartis said Tuesday that the new structure reflects the importance of oncology following the integration of oncology assets